None listed
Conditions
Interventions
Drug : A patient who has undergone liver transplantation due to hepatitis B and agrees to participate in the clinical trial one year after the surgery by signing the informed consent form will have th
Sponsors
Samsung Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients aged 19 years or older. 2. Patients who have maintained stable liver graft function for one year after liver transplantation due to HBV and meet the following conditions: ALT < 3 x ULN and AST < 3 x ULN 3. Patients taking antiviral therapy other than TAF for HBV prophylaxis. 4. Patients with a tacrolimus trough level maintained between 3-10 ng/mL. 5. Patients who have voluntarily decided to participate in the clinical trial after fully understanding the detailed explanation of the trial and have provided written consent.
Exclusion criteria
Exclusion criteria: 1. Patients who have undergone transplantation of organs other than the liver or re-transplantation. 2. Patients who have received BAL system treatment or auxiliary partial orthotopic liver transplantation (APOLT) before the transplantation. 3. Patients with concurrent viral infections (HCV, HIV). 4. Patients taking mTOR inhibitors (e.g., Everolimus (Certican), etc.). 5. Patients with eGFR <30 or those undergoing dialysis. 6. Pregnant or breastfeeding women. 7. Patients or their spouses/partners who do not agree to use medically acceptable and appropriate contraception methods* during the clinical trial period. *Appropriate contraception methods: hormonal contraception, intrauterine device (IUC or IUS), tubal ligation, tubal occlusion, hysterectomy, vasectomy, double barrier methods (combined use of male or female condoms with cervical caps, diaphragms, or contraceptive sponges), single barrier methods with spermicide. 8 . Patients with a history of hypersensitivity to Tenofovir. 9 . Patients with genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. 10 . Patients who are deemed unsuitable for participation in the clinical trial by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The amount of eGFR change after conversion compared to before TAF conversion | — |
Secondary
| Measure | Time frame |
|---|---|
| Creatinine, CKD stage, Cholesterol status, Spinal and Hip BMD status and proteinuria variation after conversion compared to before TAF conversion;HBV recurrence rate | — |
Countries
Korea, Republic of
Contacts
Public ContactJongman Kim
Samsung Medical Center
Outcome results
None listed